The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC.
R. S. Heist
Research Funding - Celgene; Genentech
G. D. Duda
No relevant relationships to disclose
D. Sahani
No relevant relationships to disclose
M. Ancukiewicz
No relevant relationships to disclose
P. Fidias
Consultant or Advisory Role - Genentech
L. V. Sequist
No relevant relationships to disclose
A. T. Shaw
No relevant relationships to disclose
J. S. Temel
No relevant relationships to disclose
I. T. Lennes
No relevant relationships to disclose
J. W. Neal
No relevant relationships to disclose
N. A. Pennell
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - Genentech
T. J. Lynch
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genentech; Merck; SuperGen
Stock Ownership - Infinity
Other Remuneration - Partners Healthcare
J. A. Engelman
No relevant relationships to disclose
R. K. Jain
Employment or Leadership Position - Enlight Biosciences; SynDevRx
Consultant or Advisory Role - Astellas Pharma; AstraZeneca; Dyax; Genzyme; Noxxon Pharma; SynDevRx
Stock Ownership - Enlight Biosciences; SynDevRx
Research Funding - Dyax; MedImmune; Roche